Posted by Reuters: Business News on December 20, 2011
LONDON/PARIS (Reuters) – Three of Europe’s biggest drugmakers — AstraZeneca , Novartis and Sanofi — reported product setbacks on Tuesday, underlining the difficulties of developing new medicines to make up for those going off patent.
Posted by Reuters: Business News on December 15, 2010
ZURICH (Reuters) – Novartis AG wrapped up its long-awaited buyout of the remainder of U.S.-listed eyecare group Alcon Inc for $12.9 billion, after sweetening its original offer with cash.
Posted by Reuters: Business News on
ZURICH (Reuters) – Novartis AG has wrapped up its long-awaited buyout of the remainder of U.S.-listed Alcon Inc
Posted by Reuters: Business News on September 22, 2010
ZURICH (Reuters) – Swiss drugmaker Novartis AG’s multiple sclerosis pill Gilenya won U.S. backing, putting it ahead of German rival Merck KGaA in the race to be first with an oral treatment in the United States.
Posted by Reuters: Business News on May 19, 2010
NEW YORK (Reuters) – Drugmaker Novartis AG must pay $250 million in punitive damages to more than 5,000 current and former women employees, a jury ruled on Wednesday, two days after finding a U.S. division of the company discriminated against women over pay, promotion and pregnancy.
Posted by Reuters: Business News on March 29, 2010
LONDON (Reuters) – British cancer specialist Antisoma suffered a body blow on Monday as a lung cancer drug being developed with Novartis failed in a late-stage trial, sending its shares plunging 70 percent.
Posted by Reuters: Business News on January 4, 2010
NEW YORK (Reuters) – U.S. stock index futures rose on Monday, as crude oil prices jumped on jitters over an oil dispute between Russia and Belarus and as drugmaker Novartis moved to buy eye care group Alcon in a $39 billion deal.
Posted by Reuters: Business News on
ZURICH (Reuters) – Swiss drugmaker Novartis aims to buy the rest of the world’s biggest eye care firm Alcon for $39.3 billion, including Nestle’s majority stake, to help it diversify away from prescription drugs.
Posted by Reuters: Business News on
ZURICH (Reuters) – Swiss drugmaker Novartis wants to buy the rest of the world’s biggest eye care firm Alcon for $39.3 billion, including Nestle’s majority stake, to help it diversify away from prescription drugs.
Posted by Reuters: Business News on
ZURICH (Reuters) – Switzerland’s Novartis agreed to buy a majority stake in eye care group Alcon for $28.1 billion, further diversifying its business away from prescription drugs to ensure more stable cash flows.
